Sarcoma

ABSTRACTS

*Duke authors bolded

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).
SESSION
Sarcoma
AUTHOR(S)
Matthew Ingham, Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark Andrew Dickson, Richard F. Riedel, Steven Attia, Anthony D. Elias, David A. Liebner, Mark Agulnik, Katherine Anne Thornton, Varun Monga, Brian Andrew Van Tine, Gary K. Schwartz, William D. Tap
ABSTRACT / POSTER 11562 ● 450

Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.
SESSION
Sarcoma
AUTHOR(S)
Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian Andrew Van Tine, Rashmi Chugh, Lee D. Cranmer, Erlinda Maria Gordon, Jason L. Hornick, David J. Kwiatkowski, Heng Du, Berta Grigorian, Anita N. Schmid, Shihe Hou, Katherine Harris, Neil Desai, Mark Andrew Dickson
ABSTRACT / POSTER 11516 ● 404